Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.03.17.995951Source: DataRank Database

Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510 is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: greenTopics (22)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Alejandra Agredo,Nadia A. Lanman ORCID,Jenna Clingerman,Kayla Gates ORCID,Andrea L. Kasinski ORCID

Live enrichment

PubMed:19767382 OpenAlex:https://openalex.org/W3012497660

National Institutes of Health

Grant: 3P30CA023168-20S1

CORE--DNA ANALYSIS

National Institutes of Health

Grant: 5R01CA205420-07

Enhancing miRNA Therapeutics through Vehicle Free Delivery

National Institutes of Health

Grant: 5R01CA205420-05

Enhancing miRNA Therapeutics through Combinatorial Targeting and Vehicle Free Delivery

greenLicense: cc-by-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2020/03/18/2020.03.17.995951.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2020.03.17.995951

repositoryhttps://doi.org/10.1101/2020.03.17.995951

https://dx.doi.org/10.1101/2020.03.17.995951

Fields of Study

Cholangiocarcinoma and Gallbladder Cancer StudiesLung Cancer Treatments and MutationsCancer-related molecular mechanisms research0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

AfatinibGefitinibCancer researchVandetanibErlotinibDownregulation and upregulationEpidermal growth factor receptorLung cancerOsimertinibMedicineCancerBiologyOncologyInternal medicineGeneGenetics

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being